This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Someone taking a weight-loss drug might leave half their dinner because they feel comfortably full. They might also stop because they feel nauseous. Measuring the leftovers would reveal the same result, but tell researchers little about why the person stopped eating.

That distinction is important when studying how GLP-1-based medications, including semaglutide and tirzepatide, affect appetite. To understand changes in eating, researchers need to record nausea alongside hunger and fullness, including when it occurs and how severe it is.

Our new review found that studies rarely examined that relationship directly. This leaves uncertainty about how much nausea influenced particular measurements of appetite and food intake.

It does not mean these drugs work mainly by making people feel sick. Separate analyses of semaglutide and tirzepatide trials suggest gastrointestinal side effects, such as nausea and vomiting, explain only a small proportion of weight loss. But understanding people's experience of eating during treatment requires more detailed measurements than many studies currently provide.

GLP-1 is a hormone released by the gut after eating. Medications that mimic its activity help regulate blood sugar and act on systems involved in appetite. They can also slow the movement of food out of the stomach. Tirzepatide, sold as Mounjaro, additionally mimics the activity of another hormone, GIP.

These medications can cause nausea, which may reduce someone's desire to eat. Simply recording that a participant experienced nausea at some point during a trial cannot show whether it affected their eating when researchers measured it.

Source link